teverelix LA (ARD-03) / Ardana Biosci - LARVOL DELTA

TEACh: Teverelix Evaluated in Advanced Prostate Cancer (clinicaltrials.gov) - P2; N=20; Not yet recruiting; Sponsor: Antev Ltd.

Clinical • New P2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

GnRH Antagonists Produce Differential Modulation of the Signaling Pathways Mediated by GnRH Receptors. (PubMed, Int J Mol Sci) - "Although immunostainings suggested that Teverelix could be less effective than Cetrorelix and Ganirelix in inhibiting 1 µM GnRH-induced β-catenin activation, Lhb gene expression increase occurring upon LβT2 cell treatment by 1 µM GnRH was similarly inhibited by all antagonists. To conclude, this study has demonstrated Cetrorelix-, Ganirelix- and Teverelix-specific biased effects at the intracellular level, not affecting the efficacy of antagonists in inhibiting Lhb gene transcription."

Journal

A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers (clinicaltrials.gov) - P1; N=48; Completed; Sponsor: Antev Ltd.; Active, not recruiting ➔ Completed; Trial primary completion date: Sep 2019 ➔ Mar 2020

Clinical • Trial completion • Trial primary completion date

Inhibition of GnRH-mediated intracellular signaling in vitro differs according to type of antagonist (ESHRE 2019) - "Wider implications of the findings: The GnRH antagonists Cetrorelix, Ganirelix and Teverelix were different with respect to in-vitro activity for inducing intracellular Ca 2+ increase. This may lead to different short-term regulation in the target cells, which could modulate the in-vivo outcomes."

Preclinical

Inhibition of GnRH-mediated intracellular signaling in vitro differs according to type of antagonist (ESHRE 2019) - "Wider implications of the findings: The GnRH antagonists Cetrorelix, Ganirelix and Teverelix were different with respect to in-vitro activity for inducing intracellular Ca 2+ increase. This may lead to different short-term regulation in the target cells, which could modulate the in-vivo outcomes."

Preclinical

Inhibition of GnRH-mediated intracellular signaling in vitro differs according to type of antagonist (ESHRE 2019) - "Wider implications of the findings: The GnRH antagonists Cetrorelix, Ganirelix and Teverelix were different with respect to in-vitro activity for inducing intracellular Ca 2+ increase. This may lead to different short-term regulation in the target cells, which could modulate the in-vivo outcomes."

Preclinical

Inhibition of GnRH-mediated intracellular signaling in vitro differs according to type of antagonist (ESHRE 2019) - "Wider implications of the findings: The GnRH antagonists Cetrorelix, Ganirelix and Teverelix were different with respect to in-vitro activity for inducing intracellular Ca 2+ increase. This may lead to different short-term regulation in the target cells, which could modulate the in-vivo outcomes."

Preclinical

A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers (clinicaltrials.gov) - P1; N=48; Active, not recruiting; Sponsor: Antev Ltd.; Recruiting ➔ Active, not recruiting; Trial completion date: Sep 2019 ➔ Dec 2019; Trial primary completion date: Jun 2019 ➔ Sep 2019

Clinical • Enrollment closed • Trial completion date • Trial primary completion date